Detail akcie Cellectar Bioscn Rg online

Business Summary: Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on to develop PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. It is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Cellectar Biosciences Inc revenues was not reported. Net loss increased 33% to $38M. Higher net loss reflects Reaserch and development increase of 45% to $27.7M (expense), General and administrative increase of 48% to $1.9M (expense), General and administrative increase of 6% to $8.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.05 to -$3.11.